HomeAbbott

Abbott

Abbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System to Treat Parkinson’s Disease

With this approval, Abbott's Infinity DBS is now the only directional DBS system approved for all major targets used to treat movement disorders, Parkinson's disease and Essential Tremor: the subthalamic nucleus (STN), ventral intermediate nucleus (VIM) and GPi. 

Abbott’s High Sensitivity Troponin-I Blood Test Receives FDA Approval

As one of the most researched troponin diagnostic tests, doctors in the U.S. can now utilize this proven technology to help detect heart attacks faster and more accurately than contemporary troponin tests.

Abbott’s HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant

10/19/18: With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives.

New Study: Abbott’s Novel Diagnostic Test Has the Potential to Demonstrate Gold Standard Accuracy and Speed

10/17/18: New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient's side in as little as 15 minutes could identify nearly three-fifths (56.7 percent) of people at low-risk of experiencing a heart attack, similar to the results of a High Sensitive Troponin-I blood test done in the laboratory setting.

Abbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling

8/2/18: Parkinson's disease and essential tremor patients can now benefit from upgraded functionality with Abbott's Infinity™ DBS system.

Five-Year Study Data Confirm Positive Outcomes for Patients When Abbott Diagnostic Tool Was Used to Guide Heart Stenting Decisions

5/22/18: "For the first time, a study has shown that patients with stable coronary artery disease who received a stent guided by an FFR diagnostic had a benefit over medical therapy alone, including fewer heart attacks and needs for urgent revascularization," said principal investigator Bernard De Bruyne, M.D., Ph.D., of the Cardiovascular Center Aalst, Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium. "Data from this study confirm the importance of FFR-guided stenting decisions combined with medical therapy over medical therapy alone."

Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter

5/3/18: "At the University of Chicago Medicine, we are passionate about understanding and redefining arrhythmia mechanisms with higher resolution cardiac mapping. Abbott's Advisor HD Grid represents an important step in the development of next generation mapping catheters. With a flexible and soft design using magnetic sensor technology, the catheter helps capture signals previous catheters may have missed to support the creation of highly detailed 3D maps of the heart," said Roderick Tung, M.D.

XIENCE Sierra™ Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

5/2/18: XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.